Results 11 to 20 of about 755,616 (163)
Antithrombotic prophylaxis in patients treated with Bruton’s tyrosine kinase inhibitors [PDF]
There is an increased risk of atrial fibrillation in patients treated with Bruton’s tyrosine kinase inhibitors such as ibrutinib or acalabrutinib. The risk of this complication, as in the general population, increases with the age of patients and the ...
Szmit, Sebastian; Department of Cardio-Oncology, Centre of Postgraduate Medical Education, Institute of Hematology and Transfusion Medicine in Warsaw, Poland; Department of Oncological Diagnostics and Cardio-Oncology, The Maria Sklodowska-Curie National Research Institute of Oncology in Warsaw,, Poland
core +1 more source
Bruton’s tyrosine kinase (BTK), a Tec family tyrosine kinase, is critical in immune pathways as an essential intracellular signaling element, participating in both adaptive and immune responses. Currently approved BTK inhibitors are irreversible covalent
Erik J. Verner (12262211) +23 more
core +2 more sources
Bruton’s tyrosine kinase (BTK), a cytoplasmic tyrosine kinase, plays a central role in immunity and is considered an attractive target for treating autoimmune diseases.
Christian Beerli +33 more
core +3 more sources
Design, Synthesis, In Vitro and In Vivo Evaluation of Cereblon Binding Bruton’s Tyrosine Kinase (BTK) Degrader CD79b targeted Antibody Drug Conjugates [PDF]
Antibody-drug conjugates (ADCs) are an established modality which allows for targeted delivery of a potent molecule, or payload, to a desired site of action.
Sebastian , Palacio-Ramirez +15 more
core +2 more sources
Mechanism of Covalent Binding of Ibrutinib to Bruton’s Tyrosine Kinase revealed by QM/MM Calculations [PDF]
Ibrutinib is the first covalent inhibitor of Bruton’s tyrosine kinase (BTK) to be used in the treatment of B-cell cancers. Understanding the mechanism of covalent inhibition is crucial for the design of safer and more selective covalent inhibitors that ...
Angus, Voice +4 more
core +1 more source
Novel Bruton’s Tyrosine Kinase (BTK) Substrates for Time-Resolved Luminescence Assays
Bruton’s tyrosine kinase (BTK) is a well-documented target for cancer therapeutics due to its role in B-cell signaling pathways. However, inhibitor design is hindered by lack of tools to assess kinase activity.
Naomi E. Widstrom (12741873) +7 more
core +4 more sources
Disruption of fyn SH3 domain interaction with a proline-rich motif in liver kinase B1 results in activation of AMP-activated protein kinase [PDF]
Fyn-deficient mice display increased AMP-activated Protein Kinase (AMPK) activity as a result of Fyn-dependent regulation of Liver Kinase B1 (LKB1) in skeletal muscle.
Bastie, Claire C. +8 more
core +1 more source
A combination of X-ray crystallography, NMR, and mass spectrometry has revealed how diverse small-molecule inhibitors bind Bruton’s tyrosine kinase and alter the conformation of this enzyme.
Ganesh Srinivasan Anand
doaj +1 more source
Primary central nervous system lymphoma (PCNSL) is a highly aggressive brain tumor with poor prognosis if no treatment. The activation of the NF-κB (nuclear factor kappa-B) is the oncogenic hallmark of PCNSL, and it was driven by B cell receptor (BCR ...
Jing Shen, Jinghua Liu, Jinghua Liu
doaj +1 more source
Reining in BTK: Interdomain Interactions and Their Importance in the Regulatory Control of BTK
Since Dr. Ogden Bruton’s 1952 paper describing the first human primary immunodeficiency disease, the peripheral membrane binding signaling protein, aptly named Bruton’s tyrosine kinase (BTK), has been the target of intense study. Dr. Bruton’s description
Lauren E. Kueffer +2 more
doaj +1 more source

